Dengue Virus 2 Envelope Antibody (201) - (Domain III)
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-05838
![Western Blot: Dengue Virus 2 Envelope Antibody (201)(Domain III) [NBP3-05838] Western Blot: Dengue Virus 2 Envelope Antibody (201)(Domain III) [NBP3-05838]](https://resources.bio-techne.com/images/products/Dengue-Virus-2-Envelope-Antibody-201-Domain-III-Western-Blot-NBP3-05838-img0001.jpg)
Conjugate
Catalog #
Key Product Details
Species Reactivity
Virus
Applications
Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # 201
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Produced in mouse immunized with recombinant Dengue Virus 2 Envelope (Accession#: AAC59274.1; Met578-Gln680).
Reactivity Notes
Dengue virus (DENV) (type 2, strain New Guinea C/PUO-218 hybrid)
Specificity
Dengue virus (DENV) (type 2, strain New Guinea C/PUO-218 hybrid) E/Envelope Protein (Domain III)
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Description
This antibody can be stored at 2C-8C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20C to -80C. Avoid repeated freeze-thaw cycles.
Scientific Data Images for Dengue Virus 2 Envelope Antibody (201) - (Domain III)
Western Blot: Dengue Virus 2 Envelope Antibody (201)(Domain III) [NBP3-05838]
Western Blot: Dengue Virus 2 Envelope Antibody (201) - (Domain III) [NBP3-05838] - Sample:Dengue virus (DENV) (type 2, strain New Guinea C/PUO-218 hybrid) E / Envelope Protein (Domain III) Recombinant ProteinLane A: 30ngSecondaryRabbit Anti-Mouse IgG (H+L)/HRP at 1/10000 dilutionPerformed under reducing conditions.Applications for Dengue Virus 2 Envelope Antibody (201) - (Domain III)
Application
Recommended Usage
Western Blot
1:1000-1:5000
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
0.2 um filtered solution in PBS
Preservative
No Preservative
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: Dengue Virus 2 Envelope
Dengue virus entry into host cells occurs via receptor-mediated endocytosis by receptor molecules including the mannose receptor, heparan sulfate, glycosaminoglycans, and DC-SIGN (1,3). Following attachment, the virus is endocytosed in clathrin-coated vesicles (1,3). Following internalization, clathrin disassembles and endosomal processing occurs, allowing viral fusion, disassembly, and release of viral RNA (1,3). This release results in viral translation and replication, virus assembly and maturation, and eventual exocytosis of the mature virus (1,3). Infection can result in a wide range of clinical symptoms including mild disease such as Dengue fever which is characterized by fever, headache, joint pain, rash, and retro-orbital pain, or severe, life-threatening conditions like Dengue hemorrhagic fever or Dengue shock syndrome which involves vascular permeability and leakage (1-3). Host immune response against infection includes innate immune response via interferon secretion and pro-inflammatory cytokine production, as well as adaptive immune response involving cellular and humoral components like T cell activation and B-cell mediated antibody production (1-3). As far as treatment for Dengue virus infection, there no commercial antiviral agents, though some anti-pyretics and certain phenolic compounds do show promise in treating infection (1-3). However, Resveratol, an antiviral for other Flavivirus, has been shown to directly attack the Dengue virus genome (1). While more work needs to be done, there are some live-attenuated tetravalent Dengue virus vaccine candidates in clinal trials including DENVax and TV003/TV005 (1-3).
References
1. Nanaware N, Banerjee A, Mullick Bagchi S, Bagchi P, Mukherjee A. Dengue Virus Infection: A Tale of Viral Exploitations and Host Responses. Viruses. 2021;13(10):1967. Published 2021 Sep 30. https://doi.org/10.3390/v13101967
2. Harapan H, Michie A, Sasmono RT, Imrie A. Dengue: A Minireview. Viruses. 2020;12(8):829. Published 2020 Jul 30. https://doi.org/10.3390/v12080829
3. Roy SK, Bhattacharjee S. Dengue virus: epidemiology, biology, and disease aetiology. Can J Microbiol. 2021;67(10):687-702. https://doi.org/10.1139/cjm-2020-0572
Alternate Names
Dengue 2 envelope;Dengue envelope;envelope protein, Envelope protein E
Additional Dengue Virus 2 Envelope Products
Product Documents for Dengue Virus 2 Envelope Antibody (201) - (Domain III)
Product Specific Notices for Dengue Virus 2 Envelope Antibody (201) - (Domain III)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...